Abstract:Background: Prostate and breast cancer are major causes of cancer-related deaths. Prostate and breast cancer are genetic diseases that develop as a result of dysregulated gene function and environmental factors. Like other cancers, many complex molecular events initiate breast cancer development. Currently, there is no clear understanding of the genetic events that govern the ability of breast cancer cells to migrate and colonize at distant sites. Importantly, however, understanding the molecular mechanisms leading to cancer metastasis may lead to the identification of novel targets for individualized therapeutic intervention. Recent studies indicate that selected miRNAs may play a role in human cancer pathogenesis. MicroRNAs are endogenous non-coding RNAs that regulate gene expression through translational repression by binding to a target mRNA. Our previous studies showed that EZH2 has properties consistent with those of an oncogene, as overexpression promotes cell proliferation, colony formation, and increased invasion of benign cells in vitro and in vivo. Methods and Results: We transfected miR-101 precursor in prostate and breast carcinoma cells and found histone methyltransferase EZH2 was decreased at both transcript and protein levels by qPCR and immunoblots. miR-101 overexpression could also inhibit EZH2-mediated cell proliferation, invasion, and anchorage-independent growth. Re-introduction of EZH2 can rescue its function repressed by miR-101. At the epigenome, introduction of microRNA-101 resulted in reduced histone H3-lysine 27 trimethylation and reactivation of EZH2 repressed tumor suppressors such as ADRB2 and E-cadherin. Furthermore, we have demonstrated that microRNA-101 expression is anti-correlated with EZH2 expression in tumor tissues. Importantly, the genomic loci of microRNA-101 are lost in prostate and breast cancer as well as other aggressive tumors overexpressing EZH2. Conclusion: Our study suggests a mechanism by which genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways resulting in cancer progression and metastasis. Approaches to re-introduce microRNA-101 into tumors may have therapeutic benefit by reverting the epigenetic program of tumor cells to a more normal state. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1492.

The EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Figure S2 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Figure S4 from The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

Figure S7 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

A PRC2-independent function for EZH2 in regulating rRNA 2′-O methylation and IRES-dependent translation

PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis

Decreased Expression of EZH2 Reactivates RASSF2A by Reversal of Promoter Methylation in Breast Cancer Cells

The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells

Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.

ZRANB1 is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.

EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis

Integrative Analysis Reveals the Transcriptional Collaboration Between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression

EZH2 Exacerbates Breast Cancer by Methylating and Activating STAT3 Directly

Regulation of EZH2 by SMYD2-Mediated Lysine Methylation is Implicated in Tumorigenesis.

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer

Abstract #1492: Role of Microrna-101 in Regulating Histone Methyltransferase EZH2 in Cancer

Autophagy deficiency activates rDNA transcription